Insiders' Blog
Sponsored by: Subscribe to EasyStockAlerts.com Now & Get The News Before Everyone Else!
Amgen (AMGN) to Halt Discounts on Aranesp -NYTimes
More News related to AMGN
- Citi Maintains 'Buy' Rating on Amgen (AMGN), Adds Stock to Top Picks Live List
- Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
- Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
- Quarterly Data Confirms Hedge Funds Exited Stocks In A Big Way
- (OTC: MNIA) MNI Nutraceuticals, Inc. Receives Purchase Order for Vital Slim
More News related to Insiders' Blog
- One Thing Separates Citi (C) From Bear and Lehman, Is It Enough?
- Merrill Smacks Down the REIT Space: Downgrades 29 Stocks, Upgrades 2
- Gold Jumps 7%, Closing In On $800/Oz
- Jim Cramer Sells His SPDR Gold Trust (ETF) (GLD)
- General Electric (GE) Sees More Insider Buying
The New York Times is reporting that Amgen (Nasdaq: AMGN) will halt pricing discounts on several of its drugs: Aranesp, Neulasta and Neupogen. According to sources, critics are saying that Amgen's rebates on its key anemia drug, Aranesp, have caused overuse of the product "at a time of mounting concerns about the product’s safety."
Amgen continues to believe that its pricing policies have not contributed to an overuse of the drug, but, "Nevertheless, we believe these contracting changes, along with other modifications, help to clear up those possible misperceptions."
Amgen has announced that the change will take effect October 1, 2008.
Amgen, Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.
Related Categories
Corporate NewsInsiders' Blog
Stocks Mentioned
+4.77Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
